Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) FCF Margin (2016 - 2023)

Historic FCF Margin for Spyre Therapeutics (SYRE) over the last 7 years, with Q2 2023 value amounting to 2419.04%.

  • Spyre Therapeutics' FCF Margin rose 8886400.0% to 2419.04% in Q2 2023 from the same period last year, while for Mar 2024 it was 15806.83%, marking a year-over-year decrease of 96681200.0%. This contributed to the annual value of 11276.52% for FY2023, which is 78337600.0% down from last year.
  • Per Spyre Therapeutics' latest filing, its FCF Margin stood at 2419.04% for Q2 2023, which was up 8886400.0% from 8906.06% recorded in Q1 2023.
  • Spyre Therapeutics' FCF Margin's 5-year high stood at 17.1% during Q2 2021, with a 5-year trough of 10797.62% in Q4 2022.
  • Moreover, its 3-year median value for FCF Margin was 2419.04% (2023), whereas its average is 4075.09%.
  • As far as peak fluctuations go, Spyre Therapeutics' FCF Margin plummeted by -102688600bps in 2022, and later skyrocketed by 8886400bps in 2023.
  • Spyre Therapeutics' FCF Margin (Quarter) stood at 528.76% in 2021, then plummeted by -1942bps to 10797.62% in 2022, then surged by 78bps to 2419.04% in 2023.
  • Its last three reported values are 2419.04% in Q2 2023, 8906.06% for Q1 2023, and 10797.62% during Q4 2022.